InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Riedel Norbert G, Director. Officer active across 6 companies, notably Eton Pharmaceuticals, Inc.. Cumulatively, 19 filings have been published. Breakdown: 1 buy · 1 sell. Total volume traded: €361k. Activity tracked since 17 May 2021. The latest transaction was disclosed on 5 August 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Riedel Norbert G
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations19 total
1,605 shares0Ordinary SharesSEC:0001161662-26-000005:0
12,500 shares@ US$7.310.0094% mcap20.5% of flowCommon StockSEC:0001437749-26-013041:0
3,415 shares@ US$138.0840.2% of flowOrdinary SharesSEC:0001161662-26-000002:0
30,000 shares@ US$4.420.014% mcap29.5% of flowCommon StockSEC:0001437749-26-003230:0
3,507 shares0Ordinary SharesSEC:0001765581-25-000082:0
27,400 shares@ US$3.5820.1% of flowCommon StockSEC:0001437749-25-000466:0
3,731 shares0Ordinary SharesSEC:0001765581-24-000077:0
46,092 sharesCommon StockSEC:0000950170-24-090806:0
10,461 sharesCommon StockSEC:0000950170-24-070725:0
3,075 shares0Ordinary SharesSEC:0001765581-23-000088:0
3,282 sharesCommon StockSEC:0000899243-23-015179:0
8,000 shares@ US$55.2856.9% of flowOrdinary SharesSEC:0001765581-22-000096:0
14,270 sharesCommon StockSEC:0000899243-22-001199:0
100,000 shares@ US$2.23100.0% of flowCommon StockSEC:0001415889-21-005779:0
Canonical exit: 6 Mar 2022 (T+90)
1,306 shares@ US$147.9616.4% of flowOrdinary SharesSEC:0001765581-21-000108:0
2,246 shares0Ordinary SharesSEC:0001765581-21-000081:0
380,000 shares0Common StockSEC:0001415889-21-002619:0
380,000 shares0Common StockSEC:0001415889-21-002573:0
12,500 sharesCommon StockSEC:0001127602-16-039325:0
19 of 19 declarations
About Riedel Norbert G
RIEDEL NORBERT G is Director at Jazz Pharmaceuticals plc, Cerevel Therapeutics Holdings, Inc., Eton Pharmaceuticals, Inc. and ARIAD PHARMACEUTICALS INC, and CEO at Aptinyx Inc. The declarant has 18 filings in total, and in the sampled recent filings the buy volume is EUR 197261 and the sell volume is EUR 163265, over the period from 2016-02-03 to 2026-04-22; the modal transaction nature is Option exercise.
